Evidence map›Paper›PMID 38956896›Full record

ArticleESC heart failure2024

Prediction of heart failure events based on physiologic sensor data in HINODE defibrillator patients.

Nobuhiro Nishii, Yasushi Sakata, Toyoaki Murohara, Kenji Ando, Takanori Ikeda, Takeshi Mitsuhashi, Akihiko Nogami, Wataru Shimizu, Torri Schwartz, Torsten Kayser and 3 more

Abstract readMulticenter Study
In one paragraph

Article in ESC heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nobuhiro NishiiDepartment of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Yasushi SakataDepartment of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
Toyoaki MuroharaDepartment of Cardiology, Nagoya University Graduate School of Medicine, Aichi, Japan.
Kenji AndoDepartment of Cardiology, Kokura Memorial Hospital, Fukuoka, Japan.
Takanori IkedaDepartment of Cardiovascular Medicine, Toho University Faculty of Medicine, Tokyo, Japan.
Takeshi MitsuhashiDepartment of Cardiology, Hoshi General Hospital, Fukushima, Japan.
Akihiko NogamiDepartment of Cardiology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Wataru ShimizuDepartment of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan.
Torri SchwartzBoston Scientific, St Paul, Minnesota, USA.
Torsten KayserBoston Scientific, Diegem, Belgium.
Caroline BeaudointBoston Scientific, Diegem, Belgium.
Kazutaka AonumaDepartment of Cardiology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
for HINODE Investigators

Funding

Boston Scientific Corporation
6 · The paper itself

Abstract

aimsHospitalizations are common in patients with heart failure and are associated with high mortality, readmission and economic burden. Detecting early signs of worsening heart failure may enable earlier intervention and reduce hospitalizations. The HeartLogic algorithm is designed to predict worsening heart failure using diagnostic data from multiple device sensors. The main objective of this analysis was to evaluate the sensitivity of the HeartLogic alert calculation in predicting worsening heart failure events (HFEs). We also evaluated the false positive alert rate (FPR) and compared the incidence of HFEs occurring in a HeartLogic alert state to those occurring out of an alert state.

methodsThe HINODE study enrolled 144 patients (81 ICD and 63 CRT-D) with device sensor data transmitted via a remote monitoring system. HeartLogic alerts were then retrospectively simulated using relevant sensor data. Clinicians and patients were blinded to calculated alerts. Reported adverse events with HF symptoms were adjudicated and classified by an independent HFE committee. Sensitivity was defined as the ratio of the number of detected usable HFEs (true positives) to the total number of usable HFEs. A false positive alert was defined as an alert with no usable HFE between the alert onset date and the alert recovery date plus 30 days. The patient follow-up period was categorized as in alert state or out of alert state. The event rate ratio was the HFE rate calculated in alert to out of alert.

resultsThe patient cohort was 79% male and had an average age of 68 ± 12 years. This analysis yielded 244 years of follow-up data with 73 HFEs from 37 patients. A total of 311 HeartLogic alerts at the nominal threshold (16) occurred across 106 patients providing an alert rate of 1.27 alerts per patient-year. The HFE rate was 8.4 times greater while in alert compared with out of alert (1.09 vs. 0.13 events per patient-year; P < 0.001). At the nominal alert threshold, 80.8% of HFEs were detected by a HeartLogic alert [95% confidence interval (CI): 69.9%-89.1%]. The median time from first true positive alert to an adjudicated clinical HFE was 53 days. The FPR was 1.16 (95% CI: 0.98-1.38) alerts per patient-year.

conclusionsResults suggest that signs of worsening HF can be detected successfully with remote patient follow-up. The use of HeartLogic may predict periods of increased risk for HF or clinically significant events, allowing for early intervention and reduction of hospitalization in a vulnerable patient population.

Indexed as

Defibrillators, ImplantableHeart FailureAgedAlgorithmsDisease ProgressionFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedPredictive Value of TestsPrognosisRetrospective StudiesCRTheart failureHeartLogichospitalizationICDremote monitoring

Identifiers

PMID38956896
PMCPMC11424318

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.